Haematex Research Pty Ltd was formed in Sydney in 2004 by scientists from Australian hospital laboratories and Gradipore/Life Diagnostics. Gradipore had international success in commercializing the dilute Russells viper venom (RVV) test for lupus anticoagulants and Haematex have developed this further to a liquid stable and more specific system.

The projects have included developing a factor Xa activated clotting test (XACT) for procoagulant phospholipid (PPL test) licenced to Diagnostica Stago. This detects prothrombotic risk in cancer and (probably) cardiac disease.

The company have developed methods for collagen, ellagic acid complex and other compounds useful in coagulation testing and blood/biomaterials research.

Most recent addition is DOAC Stop™, an activated carbon product which specifically withdraws DOACs from patient samples, thus allowing valid routine tests to be carried out despite the initial presence of DOACs.